News Merck and Pfizer stop third Bavencio ovarian cancer trial Merck and Pfizer are discontinuing the Phase III JAVELIN Ovarian PARP 100 study evaluating Bavencio (avelumab) in advanced ovarian cancer, signalling yet more disappointment for the PD-L1 immuno
News Cell Mogrify gets £420k funding for regenerative cell therap... UK cell therapy company Cell Mogrify has been awarded £420,000 funding from Innovate UK to accelerate its data-driven cell conversion programmes.
Partner Content Partner Content Immuno-Oncology 2018 News: MHRA Interview and New Speaker Im... Just Over 1 Week Until Immuno-Oncology 2018 Commences
Partner Content Partner Content MHRA, Pfizer, Autolus and Tusk Theraputics Sign Up for Immun... MHRA, Pfizer & Autolus Sign Up for Immuno-Oncology 2018
Partner Content Partner Content Less than 4 Weeks until Immuno-Therapy Experts Gather at the... Less than 4 Weeks until Immuno-Oncology Conference
News ADARx, Trex, and Retension take aim at IPOs The appetite among biotechs for IPOs shows no signs of being satisfied, with three more – ADARx, TRex, and Retension – making their intentions known.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
